SCHEMBL4786647

SCHEMBL4786647

CCCCCCCCCCCCSC[C@@H](O)CO

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.46
CES2 O00748 3/20 0.44
GMNN O75496 2/20 0.44
POLB P06746 2/20 0.44
BLM P54132 2/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44
THRB P10828 1/20 0.44
CYP2C9 P11712 1/20 0.44
HSD17B10 Q99714 1/20 0.44
PRKD3 O94806 3/20 0.43
PRKCG P05129 3/20 0.43
PRKCB P05771 3/20 0.43
PRKCA P17252 3/20 0.43
PRKCH P24723 3/20 0.43
PRKCI P41743 3/20 0.43
PRKCE Q02156 3/20 0.43
PRKCQ Q04759 3/20 0.43
PRKCZ Q05513 3/20 0.43
PRKCD Q05655 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11200004 1.00 USP2 (0.46) USP2CES2GMNNPOLBBLM
SCHEMBL4786361 1.00 USP2 (0.46) USP2CES2GMNNPOLBBLM
SCHEMBL8912364 1.00 USP2 (0.46) USP2CES2GMNNPOLBBLM
SCHEMBL5172075 1.00 USP2 (0.46) USP2CES2GMNNPOLBBLM
SCHEMBL4786370 1.00 USP2 (0.46) USP2CES2GMNNPOLBBLM
SCHEMBL11157696 1.00 USP2 (0.46) USP2CES2GMNNPOLBBLM
SCHEMBL11159944 1.00 USP2 (0.46) USP2CES2GMNNPOLBBLM
SCHEMBL11198963 1.00 USP2 (0.46) USP2CES2GMNNPOLBBLM
SCHEMBL6069252 0.98 USP2 (0.42) USP2CES2GMNNPOLBBLM
SCHEMBL5170197 0.91 USP2 (0.39) USP2CES2GMNNPOLBBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080249066-A1 ANTIVIRAL COMPOUNDS AND COMPOSITIONS ARDEA BIOSCIENCES, INC. (US) 2008-10-09 US disclosed
US-20080249066-A1 ANTIVIRAL COMPOUNDS AND COMPOSITIONS ARDEA BIOSCIENCES, INC. (US) 2008-10-09 US disclosed
US-20080249066-A1 ANTIVIRAL COMPOUNDS AND COMPOSITIONS ARDEA BIOSCIENCES, INC. (US) 2008-10-09 US disclosed
WO-2008118879-A2 ANTIVIRAL COMPOSITIONS COMPRISING 2 COMPOUNDS ARDEA BIOSCIENCES, INC. (US) 2008-10-02 WO disclosed
WO-2008118879-A2 ANTIVIRAL COMPOSITIONS COMPRISING 2 COMPOUNDS ARDEA BIOSCIENCES, INC. (US) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249066-A1 ANTIVIRAL COMPOUNDS AND COMPOSITIONS PNP, TYMP, MTAP USP2 4155/4885CES2 293/4885GMNN 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.